There is potential for further exploration of the development of a targeted therapy that induces dMMR by knockdown of MMR gene expression to combine with immune checkpoint inhibitors to increase survival of all patients with pancreatic cancer. The gene discussed is MRC1; the disease is familial pancreatic carcinoma.